TREATMENT OF FGG RELATED DISEASES AND DISORDERS

Disclosed herein are compositions comprising an oligonucleotide that targets FGG. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a mental disorder, or a condition associated with an FGG mutation. The...

Full description

Saved in:
Bibliographic Details
Main Authors CAJES, Brian, VEKICH, John, BRUSE, Shannon, GOTTESMAN, Omri, ROZEMA, David, LEWIS, David
Format Patent
LanguageEnglish
French
Published 11.07.2024
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Disclosed herein are compositions comprising an oligonucleotide that targets FGG. The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a mental disorder, or a condition associated with an FGG mutation. The method may include providing an oligonucleotide to a subject that targets FGG. L'invention concerne des compositions comprenant un oligonucléotide qui cible FGG. L'oligonucléotide peut comprendre un petit ARN interférent (ARNsi) ou un oligonucléotide antisens (ASO). L'invention concerne également des procédés de traitement d'un trouble mental, ou d'un état associé à une mutation de FGG. Le procédé peut comprendre la fourniture d'un oligonucléotide à un sujet qui cible FGG.
Bibliography:Application Number: WO2022US80933